Increasing evidence supports a role for inflammation in the development of mood disorders. In this issue of Neuron, Leng et al. (2018) show that reduction of menin expression in astrocytes of stress-related brain regions exacerbates neuroinflammation, promoting the establishment of depression-like behaviors in mice.
Major depressive disorder (MDD), the most prevalent form of depression, is often a long-lasting and recurrent psychiatric condition. It is expected that MDD will affect 20% of the population throughout lifetime (Kessler and Bromet, 2013) , and it is now considered the leading cause of disability worldwide. MDD is characterized by a constellation of symptoms including depressed mood; anhedonia; feelings of hopelessness, worthlessness, or guilt; changes in appetite, weight, and sleep; fatigue; and suicide ideation. To date, clinical diagnosis of MDD has been exclusively performed using clinical standard interviews. MDD is highly heterogeneous at biological level, raising concerns that current antidepressants do not treat adequately the pathophysiological characteristics of this disorder. In fact, pharmacological treatment is not effective for 30%-50% of patients, suggesting that it does not consider causal or secondary pathophysiological responses such as exacerbated activation of the immune system and inflammatory processes (Hodes et al., 2015) .
Inflammation has been considered a factor in the etiology of MDD since it was reported that long-term treatment with interferon-a for hepatitis can lead to psychiatric complications. Furthermore, depression co-morbidity is common in individuals suffering from inflammatory-related conditions. In response to psychological stressors, activation of the sympathetic nervous system and hypothalamus pituitary adrenal axis modulate peripheral inflammation (Hodes et al., 2015) . The innate immune system mounts a rapid response, causing peripheral immune activation and secretion of inflammatory mediators. Prolonged stress leads to immune system dysregulation and recruitment of peripheral immune cells and factors to the central nervous system (CNS), leading to central inflammation (Hodes et al., 2015) . High levels of circulating inflammatory chemokines and cytokines are frequently observed in the serum of MDD patients. In addition, resistance to antidepressant treatment was associated with elevated levels of proinflammatory cytokines, highlighting the need to take the immune system into account for an effective treatment of this mood disorder (Haroon et al., 2018) .
Astrocytes are the most abundant glial cell type in the mammalian brain and play many active roles including supportive, active, and homeostatic functions. They can also suppress neuroinflammation and protect the CNS by forming a barrier with endothelial cells and pericytes to prevent entry of inflammatory mediators (Sofroniew, 2015) . Thus, astrocytes represent an interesting target to counteract inflammation-based depression. In fact, these glial cells have been receiving increasing attention since significant abnormalities were observed in the postmortem brain of suicide completers (Torres-Platas et al., 2016) and a reduction of blood vessel coverage by astrocytic endfeet was reported in MDD subjects (Rajkowska et al., 2013) . However, mechanisms underlying dysregulation of astrocytic inflammation in the context of depression and its potential causal role in MDD pathogenesis remain largely unknown.
In this issue, Leng et al. (2018) show that astrocytic deficiency in multiple endocrine neoplasia type 1 (Men1, menin) gene leads to exacerbated neuroinflammation and the establishment of depression-like behaviors in mice ( Figure 1) . First, they observed a reduction of menin expression in the cortex and nucleus accumbens of stressed mice, two brain regions involved in depression symptomatology. MEN1 is generally considered a tumor suppressor gene in endocrine organs. MEN1 syndrome, also called Wemer's syndrome, is part of a group of disorders affecting the endocrine system and causing neoplasia. Loss-offunction MEN1 gene mutations are commonly observed in these patients, and they frequently report lower quality of life, anxiety, and depression, reinforcing a potential role for menin loss in MDD (Peipert et al., 2018) . The authors took advantage of the chronic unpredictable mild stress (CUMS) paradigm, a mouse model of depression, and lipopolysaccharide (LPS) injection, an immune challenge inducing sickness behavior, to decipher the role of menin in inflammation-based depression.
It would be interesting to evaluate in future studies if menin expression is affected in other mouse models of depression-for example, chronic social defeat stress. Indeed, the social component of this model makes it a more relevant mouse model of depression with regard to human experience. Leng et al. (2018) observed impaired social interaction in mice characterized by reduced expression of menin, suggesting that these animals could be more vulnerable to social stress. A major concern that will have to be addressed with regard to a causal role of menin deficiency in MDD pathogenesis is the possibility of sex differences. Depression is more prevalent in women, and it will be important to evaluate menin expression in stressed females. Female mice are more vulnerable to CUMS and develop depressionlike behaviors earlier than their male counterparts.
In an elegant set of experiments, the authors generated multiple lines of brain cell-type-specific conditional knockout mice and revealed through a battery of behavioral tests that lack of Men1 expression in astrocytes is driving the establishment of depression-like behaviors. This is in line with predominant expression of menin in this cell type. According to the Allen Brain Atlas, menin is widely expressed in the mouse brain, though little is known with regard to its function. It would be interesting to use a similar approach to investigate its role in other behaviors. In fact, this group recently published a study revealing a critical role for neuron-specific menin expression, with its deletion leading to synaptic dysfunction and cognitive impairment . Conversely, here downregulation of menin expression in astrocytes had no effect on spatial learning and memory. This does not rule out that menin could play a role in other forms of cognition, such as fear memory, but this remains to be explored. Importantly, Leng et al. (2018) investigated the mechanisms behind depression-like behaviors induced by lack of astrocytic Men1. To do so, the authors performed RNA sequencing in primary cortical astrocytic cultures from cell-specific conditional knockout mice, revealing significant alteration of expression of a large number of genes. Gene ontology biological process analysis identified cytokine-cytokine receptor interaction indicating that inflammatory response mediated by astrocytes may promote depression-like behaviors in the context of menin deficiency. Thus, the authors combined in vitro and in vivo experiments to demonstrate that disruption of menin binding to p65 subunit of the protein complex Nuclear Factor Kappa B (NF-kB) impairs inhibition of p65-DNA binding, resulting in increased proinflammatory interleukin-1b (IL-1b) gene transcription (Figure 1 ). Circulating IL-1b level is increased in animal models of depression and depressed individuals (Hodes et al., 2015) . To evaluate the behavioral and functional effects of NF-kB/IL-1b pathway inhibition, pharmacological experiments were conducted. Mice were treated for 7 days using either pyrrolidine dithiocarbamate (NF-kB inhibitor) or IL-1b-RA (IL-1b receptor antagonist). These treatments rescued behavioral dysfunctions in astrocytic cellspecific conditional knockout mice, reinforcing a role for this menin-driven proinflammatory signaling pathway in MDD.
To provide translational relevance to their rodent findings, the authors genotyped MEN1 coding region on chromosome 11q13.1 in a large cohort of individuals (866 controls, 1,032 MDD) and identified nine single-nucleotide polymorphisms (SNPs). They found that a T-allele SNP (rs375804228) on exon 10 of MEN1 gene inducing a G503D substitution is associated with MDD susceptibility. To confirm its causal role, the authors generated GFP-MEN1-G503D vectors and transfected HEK293T cells. They observed that this mutation abolished menin-p65 interaction and its capability to suppress p65-DNA binding and NF-kB transactivation. Important controls 
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Previews were performed by confirming that G503D substitution does not alter menin protein transcription, expression, turnover, or cellular localization. A deleterious role of G503D substitution was confirmed in human primary astrocytes and cortical Men1-deficient knockout mouse astrocytes. This set of translational experiments is intriguing; nevertheless, it will be crucial to confirm a loss of MEN1 expression in postmortem human brain samples from MDD subjects.
The discovery of a biomarker to improve MDD diagnosis is one of the major challenges in the field. Many efforts have been undertaken in order to detect genetic variations or circulating biomarkers that could be used for diagnosis, prevention, or predictor of treatment response. Several SNPs were flagged as risk factors. However, MDD is a complex disease so far not predictable by only one gene alteration but rather by several small genetic variations along with many environmental factors. Discovery of a MEN1 gene SNP promoting susceptibility for depression raises the possibility in the near future of a genetic diagnostic for MDD that could include a set of small-effect SNPs with big influence when observed altogether. However, the importance of MEN1 SNP in MDD must first be independently confirmed. With regard to the development of biomarkers, menin can be found in the nucleus and cyto-plasm but also the extracellular space. Astrocyte-related markers have already been targeted as potential biomarkers of MDD. S100B, a protein primarily produced by astrocytes, is elevated in the blood serum of MDD patients, and antidepressant treatment lowers S100b level in parallel with depressive symptoms (Schroeter et al., 2002) . In a clinical perspective, it would be worth evaluating whether menin could be detected in the serum of MDD patients and if it could be associated to symptom severity and remission. Caution is required because menin is a protein found in other organs, not only the CNS. Nevertheless, since recent evidence suggests that stress-induced inflammation disrupts the blood-brain barrier, an elevation of circulating menin level could represent an interesting alternative to diagnose a subpopulation of MDD patients presenting specific biological characteristics such as astrocyte-driven neuroinflammation.
